阿托伐他汀钙治疗急性肺栓塞的疗效及其对炎症因子、血小板功能的影响  

Effect of atorvastatin calcium on inflammatory factor and platelet function in patients with acute pulmonary embolism

作　　者：胡家顺 兰为群 易琨 文媛[1] 刘少文 舒逸[1] 刘芳琳 赵世明 Hu Jiashun;Lan Weiqun;Yi Kun;Wen Yuan;Liu Shaowen;Shu Yi;Liu Fanglin;Zhao Shiming(Department of Cardiovascular Medicine,Wuhan Hankou Hospital,Wuhan 430012,Hubei,China;Department of Hepatobiliary Gastrointestinal Vascular Surgery,Wuhan Hankou Hospital,Wuhan 430012,Hubei,China)

机构地区：[1]武汉市汉口医院心血管内科,湖北武汉430012 [2]武汉市汉口医院肝胆胃肠血管外科,湖北武汉430012

出　　处：《血管与腔内血管外科杂志》2022年第9期1120-1123,1129,共5页Journal of Vascular and Endovascular Surgery

摘　　要：目的探讨急性肺栓塞患者应用阿托伐他汀钙的治疗效果,并分析其对患者炎症因子、血小板功能的影响。方法选取2020年2月至2021年2月武汉市汉口医院收治的98例急性肺栓塞患者,按照随机数字表法将患者分为对照组(n=49,给予低分子肝素和华法林常规治疗)和观察组(n=49,在对照组基础上加用阿托伐他汀钙治疗)。比较两组患者的血栓清除率、症状消失时间、炎性因子水平、血小板功能、不良反应发生率及复发率。结果治疗3个月后,观察组患者血栓清除率为95.92%(47/49),高于对照组患者的83.67%(41/49),差异有统计学意义(P<0.05)。观察组患者呼吸困难、胸痛、发绀消失时间均明显短于对照组患者,差异均有统计学意义(P<0.01)。治疗后,观察组患者肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平均低于对照组患者,差异均有统计学意义(P<0.05)。治疗后,观察组患者血小板聚集率(PAgT)、黏附性(PAdT)、膜糖蛋白(GPⅡb/Ⅲa)均低于对照组患者,差异均有统计学意义(P<0.05)。两组患者不良反应总发生率及复发率比较,差异均无统计学意义(P>0.05)。结论应用阿托伐他汀钙治疗可改善急性肺栓塞患者的机体炎性反应和血小板功能,促进血栓清除,改善患者的临床症状,安全性较好。Objective To investigate the therapeutic effect of atorvastatin calcium in patients with acute pulmonary embolism and its effect on inflammatory factor and platelet function.Method A total of 98 patients with acute pulmonary embolism who were admitted to Wuhan Hankou Hospital from February 2020 to February 2021 were selected.The patients were divided into control group(n=49,given the routine treatment of low molecular weight heparin and warfarin)and observation group(n=49,given atorvastatin calcium treatment on the basis of the control group)according to the random number table method.The thrombus clearance rate,symptom disappearance time,inflammatory factor levels,platelet function,the incidence of adverse events,and recurrence rates were compared between the two groups.Result After 3 months of treatment,the thrombus clearance rate in the observation group was 95.92%(47/49),higher than that in the control group with 83.67%(41/49),the difference was statistically significant(P<0.05).The disappearance time of dyspnea,chest pain,and cyanosis in the observation group were significantly shorter than those of the control group,the differences were statistically significant(P<0.01).After the treatment,the levels of tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After the treatment,the platelet aggregation rate(PAgT),adhesion(PAd T)and membrane glycoprotein(GPⅡb/Ⅲa)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences in the total incidence of adverse events and the recurrence rate between the two groups(P>0.05).Conclusion Atorvastatin calcium treatment for patients with acute pulmonary embolism could improve the body’s inflammatory response and platelet function,promote thrombus removal,and alleviate the clinical symptoms of patients with good safety.

关 键 词：急性肺栓塞 阿托伐他汀钙 炎症因子 血小板功能 

分 类 号：R543[医药卫生—心血管疾病]